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Ps. aeruginosaAbstract A simple methodology was developed to evaluate binding efﬁciency of antibiotic mem-
bers of ﬂuoroquinolones, namely ciproﬂoxacin, oﬂoxacin and enorﬂoxacin, complexed with 99mTc,
against Escherichia coli, Salmonella and Pseudomonas aeruginosa bacterial strains. Radioactivity in
the pellet, tips supernatant and micro-centrifugation tubes was counted separately for 5 s in a
sodium iodide well-counter with dedicated nuclear medicine software. The overall percentage activ-
ity of the live and killed bacteria was found in the range of 5–46% with different types of labelled
quinolones and bacteria. Activity of the labelled enorﬂoxacin and ciproﬂoxacin indicated acceptable
results for both live and killed E. coli and Ps. aeruginosa. However, oﬂoxacin was found to be
moderate for all the live bacterial stains. This developed methodology has achieved more than
95% labelling efﬁciency of 99mTc with derivatized quinolones and also the observed results
indicated that these complexes may be used as an infection speciﬁc imaging agents.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Scintigraphic imaging of infection and inﬂammation is a
powerful diagnostic tool in the management of patient with
infectious diseases. Most infections and inﬂammatory foci
may be seen accurately with radio labelled autologous
leukocytes. The preparation of these radiopharmaceuticals is
laborious and requires the handling of contaminated blood.
Figure 1 Essential structure of all quinolone antibiotics: the blue
drawn remainder of R is usually piperazine; if the connection
contains ﬂuorine (red), it is a ﬂuoroquinolone.
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instead of radio-labelled leukocytes to scintigraphically visual-
ize infections and inﬂammation foci, such as 99mTc labelled
antigranulocyte antibody and 67Ga-citrate.1 Various agents
labelled with 99mTc have been developed for this application.
Most of these newly developed agents are those that bind
receptors on white blood cells subpopulations, i.e. monoclonal
antibodies, chemotactic peptides and cytolines.1 The ideal
radiopharmaceutical for imaging infection/inﬂammation
should be efﬁciently accumulated and has good retention in
inﬂammation foci. Moreover, it should have rapid clearance
from the background with no accumulation in non-inﬂamed
tissues, no side effects, low cost (99mTc), easy preparation
(kit formation), and should have the ability to discriminate
infection from non-microbial inﬂammation cells.
67Ga-citrate has been widely used for imaging infection and
inﬂammation ever since its discovery in 1971. On intravenous
injection, 67Ga-citrate binds to transferring and this complex
extravagates at the site of inﬂammation because of the locally
enhanced vascular permeability.2–4 This use of radio-labelled
autologous leukocytes for imaging infection and inﬂammation
has been a major breakthrough in radio-labelled imaging
because they rapidly clear from the blood and migrate actively
from the circulation into the infected tissues.5–7Also the use of
radio-labelled monoclonal antibodies against surface antigens
of granulocytes was one of the ﬁrst attempts to accomplish
in-vivo labelling of leukocytes.
Now several monoclonal antibodies reactive with antigens
expressed on granulocytes have been developed,1 and each of
these anti-granulocyte antibodies with 99mTc allowed the accu-
rate delineation of infection and inﬂammation. Rubin et al.8
used radio-iodinated IgG as a control in an experiment to
image Pseudomonas aeruginosa infection with a radio-labelled
monoclonal antibody against a surface epitope of the Pseudo-
monas bacterium and observed that the control antibody visu-
alized the good infectious focus as the anti-Pseudomonas
antibody did. They proposed the use of non-speciﬁc IgG as
an infection and inﬂammation imaging agent. The litera-
ture1,5–9 indicated that different radio-labelled compounds like
67Ga-Citrate, radio-labelled leukocytes (white blood cells-
WBCs), labelled antigranulocyte antibodies, radio-labelled
non-speciﬁc human IgG, anti-e-selection antibodies, radio-
labelled liposomes, bacterial chemotactic peptides, Interleu-
kin-1, 2 and 8, Tuftsin, platelet factor-4, and antimicrobial
peptides have been investigated for imaging infections and
inﬂammations.
None of the agents discussed above can discriminate
between infection and inﬂammation, because of their binding
to the DNA gyrase enzyme present in all dividing bacteria.
Fluoroquinolones does not accumulate in dead bacteria and
non-inﬂammatory sites. Ciproﬂoxacin is a ﬂuoroquinolone
antimicrobial agent that binds with the gyrase enzyme, even
to those resistant to ciproﬂoxacin. It is stated9 that 99mTc-
labelled ciproﬂoxacin can distinguish between infection and
sterile inﬂammation. Another study10 indicated that it also
shows high accuracy in the detection of bacterial infection.
Preliminary studies with sparﬂoxacin, norﬂoxacin, peﬂoxacin,
and lomeﬂoxacin derivatives have shown signiﬁcant in-vitro
uptake in bacteria as well as accumulation in sterile inﬂamma-
tory sites. Critical evaluation of these investigated com-
pounds11–15 was warranted to ultimately prove their value
for speciﬁc imaging of infections.Quinolones are a family of synthetic broad spectrum anti-
bacterial drugs. The essential structure of all quinolone antibi-
otics is given in Fig. 1. Fluoroquinolones are antibiotics that
are commonly used to treat a variety of illnesses such as respi-
ratory and urinary tract infections. These medicines include
ciproﬂoxacin (Cipro), gemiﬂoxacin (Factive), levoﬂoxacin
(Levaquin), moxiﬂoxacin (Avelox), norﬂoxacin (Noroxin),
and oﬂoxacin (Floxin). In the present work, 99mTc labelling
has been carried out with derivatized ciproﬂoxacin, oﬂoxacin
and enorﬂoxacin to investigate their accumulation in both live
and dead Escherichia coli, Salmonella and Ps. aeruginosa bac-
terial strains.
2. Material and methods
All reagents and solvents used in this study were of reagent
grade purity and were used without further puriﬁcation. All
apparatus used were freshly autoclaved and were free from
any micro-organisms. Experiments were performed in tripli-
cate and the results reported were the average of triplicates.
The isolated bacterial stains, obtained from the department
of zoology, University of the Punjab, were identiﬁed as
E. coli, Salmonella and Ps. aeruginosa bacterial strains, and
were incubated in different ﬂask mediums by using the stan-
dard conditions of laminar ﬂow chamber.
The bacterial cultures were poured into falcon tubes and
centrifuged at 16,000 rpm in freezing conditions for 10 min
to convert them into supernatant and pellets. The pellets were
dissolved in autoclaved solvent solution. The suspensions were
checked for their optical density and diluted enough to give the
solvents of 0.14 optical densities which referred to approxi-
mately 1.00 · 108 cfu/mL of each stain. The bacteria were
not multiplying during the study. Half of each aliquot was
taken into a separate sterile tube and was heated at 70 C for
40 min in a water bath. 1.00 mL sample from all killed suspen-
sions of bacterial stains was placed in sterile glass tubes to con-
ﬁrm their sterility and cell morphology. No liability was found
in any of these controls and the morphology was similar to
that of the original stains from fresh culture.
Each sample was evaluated after 30 min, 1.0 h and 4.0 h of
incubation interval with 99mTc-ﬂuoroquinolones or 99mTc
(blank) at room temperature. Experiments for each labelled
ﬂuoroquinolones were conducted on three separate days, so
that 12 samples from each group were evaluated. The 99mTc-
ﬂuoroquinolone was constituted on experimental days.16
2.1. Pertechnetate kit formation
Each of ciproﬂoxacin, oﬂoxacin and enorﬂoxacin kit con-
tained the following constituents: 3.00 mg of ﬂuoroquinolones,
3.00 mg of cysteine monohydrochloride, 2.00 mg of ascorbic
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Figure 3 Complex formation of 99mTc-enorﬂoxacin.
In-vitro binding assay study of ﬂouroquinolones 49acid, 20.00 mg of NaCl dissolved in 800 lL distilled water,
mixed on stirring and followed by addition of 200.00 lg of
SnCl2Æ2H2O from a solution containing 100.00 mg stannous
tartrate in 0.4 mL conc. HCl by gentle heating and diluted
up to 10 mL with distilled water. pH was adjusted to 4.5 by
using 0.1 N HCl/0.1 N NaOH solutions. Stability of pH value
was monitored for 15 min during the stirring process. After
lyophilization, the freeze dried kits were stored at 4 C.
2.2. Radio-labelling of kit
For radio-labelling of the freeze dried kits, sodium per techn-
etate (300 MBQ) was drawn up from a freshly eluted in-house
developed ‘Sterile PAKGEN 99Mo/99mTc generator’16 (PINS-
TECH, Islamabad-Pakistan), and put into the vials containing
ciproﬂoxacin, oﬂoxacin and enorﬂoxacin kits by using insulin
syringes. The vials were shaken for 30 s, incubated at room
temperature for 10–15 min, and volume was brought to
1.00 mL by using saline solution (0.9% NaCl). Quality control
of the radio-labelled kits was performed with the help of paper
chromatography in acetone and ITLC (instant thin layer chro-
matography). Reaction mechanisms of 99mTc with studied
antibiotics are reported in Figs. 2–4. The labelling efﬁciency
of ﬂuoroquinolones with 99mTc is reported in Table 1.
2.3. Radiopharmaceutical incubation and measurement
Culture reviving and heat killing of bacterial stains are
repeated as follows; 1.00 mL of each sample was withdrawn
in a sterile glass pipette and placed in a polypropylene
micro-centrifugation tube (VWR international). 50 lL 99mTc-
ﬂuoroquinolones along with 50 lL 99mTc (blank) were placed
in each sample of live or killed bacterial stains. At the spent
of time, each sample tube was spun on 14,000 rpm (Eppendorf
Minispin Plus Microcentrifuge) at 4 C for 5 min. The super-
natant was transferred via micro pipette (Redi-IPS Fisher
brand) to a new sterile glass tube. The pellet was re-suspended
with 1.00 mL sterile saline solution and centrifuged. The re-
suspended supernatant was added to initial supernatant. This
pellet was then transferred via pipette into a new sterile glass
test tube. This pipette tip was saved, as the bacteria within it
could not be completely evacuated. Radioactivity in the pipetteN
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Figure 2 Complex formation of 99mTc-ciproﬂoxacin.tip was considered to be the part of bacterial pellet. Transfer of
the pellet to a new glass test tube was necessary due to some
binding of 99mTc-quinolones to the micro-centrifugation tube,
which was then preserved and considered the part of superna-
tant after being washed with 1.00 mL of sterile saline solution.
The radioactivity in the pellet, tips supernatant and micro-
centrifugation tubes was counted separately for 5 s in a sodium
iodide well counter equipped with dedicated nuclear medicine
software. The percentage of total activity in the pellet was cal-
culated as follows:
% total activity ¼ Pellet activity
Pellet activityþ Supernatantactivity 100
ð1Þ
The results thus obtained for each labelled antibiotics for
live and killed microbes and for blank solution after 30 min,
1 h and 4 h are reported in Table 2.3. Results and discussion
The results obtained are discussed under the following
headings.
3.1. Labelling efﬁciency of ﬂuoroquinolones with 99mTc
In this study, three ﬂuoroquinolones were labelled with 99mTc
and their activity was checked against three bacterial stains.
The radiochemical purity was checked with the help of paper
chromatography in acetone and instant thin layer chromatog-
raphy (ITLC) in saline. For all the radio labelled antibiotics,
the labelling efﬁciency was more than 95%, which shows
promising chemical purity for the present study. Labelling efﬁ-
ciency of three antibiotics (Table 1) indicates that minute
amount of free TcO4
1 (pertechnetate) and prominent amount
of colloid formation results during complex formation. All the
three quinolones showed similar behaviour for both paper and
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Figure 4 Complex formation of 99mTc-oﬂoxacin.
Table 1 Labelling efﬁciency of 99mTc with ﬂuoroquinolones.
Sr. no Antibiotic Labelling
eﬃciencies (%)
Colloid Free TcO4
1
1 Ciproﬂoxacin >96 2.27 ± 0.12 0.80 ± 0.03
2 Enorﬂoxacin >95 3.45 ± 0.10 1.50 ± 0.02
3 Oﬂoxacin >97 2.05 ± 0.09 0.95 ± 0.02
50 M.A. Qadir et al.ITLC. The colloidal remains at the origin, while free TcO4
1
moved along the solvent front. The labelling of the ﬂuoroquin-
olones was determined by the formula:
% of labelled fluoroquinolones
¼ 100 ð% activity of colloidsþ% activity of TcO14 Þ ð2Þ3.2. Binding assay of labelled ﬂuoroquinolones with bacteria
The stains of bacteria used in this research were commonly
infection causing pathogens. The overnight culture of bacte-
ria’s was incubated and approximately, 1.0 · 108 cfu/mL was
conformed by optical density. Table 2 shows negligible binding
efﬁciency of free 99mTc with bacterial stains at three different
intervals, as compared to binding efﬁciencies of 99mTc-
ﬂouroquinolones.
3.3. Activity of 99mTc-ciproﬂoxacin in live and killed bacteria
99mTc-ciproﬂoxacin showed an un-expected behaviour of accu-
mulation in both live and killed bacteria. The activity of 99mTc-
ciproﬂoxacin in live E. coli after 30 min, 1.0 h and 4.0 h was 37,
27 and 34%, respectively, with an average of 33%, while in
killed E. coli its activity was 46, 39 and 40% with an average
of 42%, which is about 10% more than that of live E. coli.The activity of 99mTc-ciproﬂoxacin in live Salmonella after
30 min, 1.0 h and 4.0 h was 22, 34 and 29%, respectively, with
an average of 28%. In killed salmonella, its activity was 43, 37
and 47%, respectively, with an average of 42%, it is also 14%
more than live Salmonella. The activity of 99mTc-ciproﬂoxacin
in Ps. aeruginosa after 30 min, 1.0 h and 4.0 h was 46, 42 and
37%, respectively, with an average of 42%, while in killed Ps.
aeruginosa, its activity was 37, 39 and 37%, respectively, with
an average of 38%, which is 4% less than the live Ps. aerugin-
osa. We may say that 99mTc-ciproﬂoxacin binds with both live
and killed bacteria under the study. Our ﬁnding contradicts
with the other workers9,10, who state that ﬂuoroquinolones
are thought not to bind to dead as well as in non-microbial
inﬂammatory processes. The behaviour of 99mTc-ciproﬂoxacin
indicates that it not only participates in binding with gyrase
but also with other parts of the pathogens as well.
3.4. Activity of 99mTc-oﬂoxacin in live and killed bacteria
The behaviour of 99mTc-oﬂoxacin was different from that of
99mTc-ciproﬂoxacin. The activity of 99mTc-oﬂoxacin in live
E. coli, Salmonella and Ps. aeruginosa was higher than those
of killed ones. The activity of 99mTc-oﬂoxacin in live E. coli
after 30 min, 1.0 h and 4.0 h was 34, 41 and 41%, respectively
with an average of 39%, while in killed E. coli its activity was
5, 19 and 13% with an average of 9%, which is 30% less than
that of live E. coli. Similarly the activity of 99mTc-oﬂoxacin in
live Salmonella was 46, 49 and 46% after 30 min, 1.0 h and
4.0 h respectively, with an average of 47%. However, its activ-
ity in killed Salmonella was 6, 10, and 17% with an average of
11%. This value (36%) is less than live cell activity. The activ-
ity of 99mTc-oﬂoxacin in Ps. aeruginosa live cells was 10, 31 and
46% with an average of 29% after 30 min, 1.0 h and 4.0 h
respectively. Its activity in dead cells was 8, 31 and 46% with
an average of 28%. This ﬁgure is also less than 1% to that
Table 2 Activity of free 99mTc1 and labelled ﬂuoroquinolones on live and killed bacteria after different time intervals.
Labelled compound Live or killed
stains
Bacterial species Activity (%)
after 30 min
Activity (%)
after 1.0 h
Activity (%)
after 4.0 h
Average
activity (%)
Free 99mTc1 Live stains E. coli 0.11 0.02 0.05 0.06
Salmonella 0.11 0.12 0.04 0.09
Ps. aeruginosa 0.02 0.01 0.04 0.02
Killed stains E. coli 0.00 0.19 0.07 0.09
Salmonella 0.00 0.12 0.06 0.06
Ps. aeruginosa 0.05 0.12 0.11 0.09
99mTc-ciproﬂoxacin Live stains E. coli 37 27 34 32.67
Salmonella 22 34 29 28.33
Ps. aeruginosa 46 42 37 41.67
Killed stains E. coli 46 39 40 41.67
Salmonella 43 37 47 42.33
Ps. aeruginosa 37 39 37 37.67
99mTc-oﬂoxacin Live stains E. coli 34 41 41 38.67
Salmonella 46 49 46 47.00
Ps. aeruginosa 10 31 46 29.00
Killed stains E. coli 5 19 13 12.33
Salmonella 6 10 17 11.00
Ps. aeruginosa 8 31 46 28.33
99mTc-enorﬂoxacin Live stains E. coli 45 48 44 45.67
Salmonella 34 47 38 39.67
Ps. aeruginosa 21 16 14 17.00
Killed stains E. coli 44 36 13 31.00
Salmonella 49 27 19 31.67
Ps. aeruginosa 29 35 26 30.00
In-vitro binding assay study of ﬂouroquinolones 51of live cell activity. As stated above, this difference in the activ-
ities of 99mTc-oﬂoxacin in all three types of pathogens and the
activity of 99mTc-oﬂoxacin is almost two to three folds more in
live cells than those of killed ones. There is much more possi-
bility of binding of 99mTc-oﬂoxacin to gyrase enzyme and our
ﬁnding supports the ﬁndings of other workers.9,10
3.5. Activity of 99mTc-enorﬂoxacin in live and killed bacteria
The activity of 99mTc-enorﬂoxacin after 30 min, 1.0 h and 4.0 h
in live E. coli was 45, 48 and 44%, respectively, with an aver-
age of 46%, while its activity in killed E. coli was 44, 36 and
13%, respectively, with an average of 31%. This activity indi-
cates a decreasing behaviour with time. The activity of 99mTc-
enorﬂoxacin in Salmonella was 34, 47 and 38% with an aver-
age of 40% after 30 min, 1.0 h and 4.0 h respectively. The
activity of 99mTc-enorﬂoxacin in killed Salmonella was 49, 27
and 19%, respectively, and it again showed a decreasing activ-
ity trend with time, with an average of 32%. The activity of
99mTc-enorﬂoxacin in live Ps. aeruginosa was 21, 16 and
14% after 30 min, 1.0 h and 4.0 h respectively, with an average
of 17%. The activity of 99mTc-enorﬂoxacin in Ps. aeruginosa
was about 50% less than that of other live pathogens. The
activity of 99mTc-enorﬂoxacin in dead Ps. aeruginosa after
30 min, 1.0 h and 4.0 h was 29, 35 and 26% with an average
of 30%. Overall, in case of 99mTc-enorﬂoxacin, the activity
in dead cells was once again prominent. Therefore, we may
conclude that it is not necessary that all ﬂuoroquinolones do
not act with dead pathogens as they bind with gyrase enzyme
as well as with other microbial stuffs.11–14
The relative high activities of 99mTc-ciproﬂoxacin in both
live and dead pathogens suggests that it may be used forimaging all three types of microbes, while 99mTc-oﬂoxacin
may be used for imaging live E. coli and Salmonella and to les-
ser extent live Ps. aeruginosa (29% activity). 99mTc-enorﬂoxa-
cin showed excellent activity in live and dead cells except live
Ps. aeruginosa with activity of only 17%. 99mTc-enorﬂoxacin
activity in both E. coli and Salmonella live and a dead cell
was moderate. In-vitro studies of these complexes indicate that
they may be used for imaging speciﬁc infection.4. Conclusion
Our study indicates that on an average, 99mTc-ciproﬂoxacin
showed 33% and 42% activity in live and killed E. coli, 28%
and 43% activity in live and killed Salmonella and 42% and
38% activity in live and killed Ps. aeruginosa. The accumula-
tion of 99mTc-ciproﬂoxacin was higher in dead cells of E. coli
and Salmonella, and live Ps. aeruginosa. The accumulation of
99mTc-oﬂoxacin in live and dead E. coli was 39% and 12%
respectively, while in Salmonella it was 47% and 11% in live
and dead pathogens. The activity of 99mTc-oﬂoxacin in Ps.
aeruginosa live and killed was 29% and 28% respectively.
These results indicate that 99mTc-oﬂoxacin accumulates more
than three times in live cells. 99mTc-enorﬂoxacin activity in
both E. coli and Salmonella live and dead cells was moderate
except for live Ps. aeruginosa where its activity was found to
be only 17%. 99mTc-oﬂoxacin may be used for imaging all
three live pathogens, while 99mTc-oﬂoxacin and 99mTc-enor-
ﬂoxacin may be used for imaging both live and dead patho-
genic infections. All these labelled compounds showed
reasonable activity even after 4 h. All these properties indicate
that these compounds may be tested for imaging infections.
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